Lexicon Pharmaceuticals (LXRX) Receivables (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Receivables data on file, last reported at $11.8 million in Q1 2026.

• Receivables for Q1 2026 came in at $11.8 million, down 75.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.8 million (down 75.17% YoY), and the FY2025 annual result was $2.4 million, down 31.36% from the prior year.
• Receivables grew to $11.8 million in Q1 2026 per LXRX's latest filing, from $2.4 million in the prior quarter.
• Over five years, Receivables peaked at $47.4 million in Q1 2025 and troughed at $28000.0 in Q4 2022.
• A 5-year average of $4.7 million and a median of $1.5 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables tumbled 78.62% in 2022, then jumped 3507.14% in 2023.
• A 5-year view of Receivables shows it stood at $28000.0 in 2022, then jumped by 3507.14% to $1.0 million in 2023, then surged by 243.86% to $3.5 million in 2024, then slumped by 31.36% to $2.4 million in 2025, then jumped by 394.09% to $11.8 million in 2026.
• Business Quant data shows LXRX's Receivables at $11.8 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.